Compare Stocks: RFAI, PALI, ZNTL, and IKT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKT Inhibikase Therapeutics	$2.42 +0.2%	$2.05	$1.33 ▼ $2.53	$336.99M	0.95	1.24 million shs	131,745 shs
PALI Palisade Bio	$2.14 -0.7%	$1.95	$0.53 ▼ $2.86	$372.07M	1.52	3.79 million shs	1.16 million shs
RFAI RF Acquisition Corp II	$11.07 +0.0%	$11.05	$10.58 ▼ $11.44	$92.36M	N/A	26,836 shs	1,998 shs
ZNTL Zentalis Pharmaceuticals	$3.61 -13.1%	$4.34	$1.21 ▼ $6.95	$258.37M	1.92	1.64 million shs	3.52 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKT Inhibikase Therapeutics	+0.42%	0.00%	+16.99%	+39.31%	+240,999,900.00%
PALI Palisade Bio	+9.69%	+2.87%	+11.40%	+17.49%	+165.17%
RFAI RF Acquisition Corp II	+0.05%	-0.14%	+0.05%	+1.05%	+4.63%
ZNTL Zentalis Pharmaceuticals	-3.26%	-17.00%	-13.00%	+2.47%	+178.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKT Inhibikase Therapeutics	$2.42 +0.2%	$2.05	$1.33 ▼ $2.53	$336.99M	0.95	1.24 million shs	131,745 shs
PALI Palisade Bio	$2.14 -0.7%	$1.95	$0.53 ▼ $2.86	$372.07M	1.52	3.79 million shs	1.16 million shs
RFAI RF Acquisition Corp II	$11.07 +0.0%	$11.05	$10.58 ▼ $11.44	$92.36M	N/A	26,836 shs	1,998 shs
ZNTL Zentalis Pharmaceuticals	$3.61 -13.1%	$4.34	$1.21 ▼ $6.95	$258.37M	1.92	1.64 million shs	3.52 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKT Inhibikase Therapeutics	+0.42%	0.00%	+16.99%	+39.31%	+240,999,900.00%
PALI Palisade Bio	+9.69%	+2.87%	+11.40%	+17.49%	+165.17%
RFAI RF Acquisition Corp II	+0.05%	-0.14%	+0.05%	+1.05%	+4.63%
ZNTL Zentalis Pharmaceuticals	-3.26%	-17.00%	-13.00%	+2.47%	+178.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	125.00% Upside
PALI Palisade Bio	3.00	Buy	$9.00	333.73% Upside
RFAI RF Acquisition Corp II	2.00	Hold	N/A	N/A
ZNTL Zentalis Pharmaceuticals	2.33	Hold	$6.75	90.19% Upside

Current Analyst Ratings Breakdown

Latest RFAI, PALI, ZNTL, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/23/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/23/2026	ZNTL Zentalis Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ZNTL Zentalis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/14/2026	PALI Palisade Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	IKT Inhibikase Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/6/2026	ZNTL Zentalis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/30/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
6/30/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IKT Inhibikase Therapeutics	$260K	1,288.06	N/A	N/A	$2.30 per share	1.04
PALI Palisade Bio	$250K	1,446.44	N/A	N/A	$0.87 per share	2.39
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	3.77	N/A	N/A	$2.99 per share	1.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-44.00%	-41.90%	N/A
PALI Palisade Bio	-$16.78M	-$1.01	N/A	N/A	N/A	N/A	-36.86%	-34.89%	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-64.23%	-48.16%	N/A

Latest RFAI, PALI, ZNTL, and IKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/7/2026	Q2 2026	RFAI RF Acquisition Corp II	N/A	$0.01	N/A	$0.01	N/A	N/A
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IKT Inhibikase Therapeutics	N/A	30.14	30.14
PALI Palisade Bio	N/A	23.71	23.71
RFAI RF Acquisition Corp II	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	6.19	6.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IKT Inhibikase Therapeutics	3.81%
PALI Palisade Bio	11.79%
RFAI RF Acquisition Corp II	N/A
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
IKT Inhibikase Therapeutics	7.10%
PALI Palisade Bio	0.07%
RFAI RF Acquisition Corp II	39.10%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IKT Inhibikase Therapeutics	6	139.54 million	122.66 million	N/A
PALI Palisade Bio	10	174.27 million	174.15 million	Not Optionable
RFAI RF Acquisition Corp II	N/A	8.34 million	5.08 million	N/A
ZNTL Zentalis Pharmaceuticals	160	71.67 million	68.95 million	Optionable

RFAI, PALI, ZNTL, and IKT Headlines

Recent News About These Companies

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14 at 9:16 AM | finance.yahoo.com

Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share

August 14 at 9:16 AM | msn.com

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

August 13 at 10:23 PM | globenewswire.com

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

August 13 at 4:01 PM | globenewswire.com

HC Wainwright Analysts Decrease Earnings Estimates for ZNTL

August 11 at 7:41 AM | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Rating Lowered to "Strong Sell" at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen

August 8, 2026 | marketbeat.com

Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL

August 7, 2026 | marketbeat.com

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

August 6, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

August 6, 2026 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Zentalis Pharmaceuticals (ZNTL) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

Rodman & Renshaw Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

July 23, 2026 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages

July 22, 2026 | marketbeat.com

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?

July 20, 2026 | zacks.com

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

July 17, 2026 | globenewswire.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at Mizuho

July 17, 2026 | marketbeat.com

Zentalis Pharmaceuticals Insider Trading Activity | NASDAQ:ZNTL | Benzinga

June 30, 2026 | benzinga.com

Zentalis Shareholders Back Directors, Auditors and Executive Pay

June 18, 2026 | tipranks.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

May 27, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFAI, PALI, ZNTL, and IKT Company Descriptions

Inhibikase Therapeutics NASDAQ:IKT

$2.42 +0.01 (+0.21%)

As of 03:42 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Palisade Bio NASDAQ:PALI

$2.13 -0.02 (-0.70%)

As of 03:43 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

RF Acquisition Corp II NASDAQ:RFAI

$11.07 +0.00 (+0.04%)

As of 03:42 PM Eastern

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$3.60 -0.55 (-13.13%)

As of 03:43 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RFAI, PALI, ZNTL, and IKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RFAI, PALI, ZNTL, and IKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RFAI, PALI, ZNTL, and IKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFAI, PALI, ZNTL, and IKT Company Descriptions

Inhibikase Therapeutics NASDAQ:IKT

Palisade Bio NASDAQ:PALI

RF Acquisition Corp II NASDAQ:RFAI

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RFAI, PALI, ZNTL, and IKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RFAI, PALI, ZNTL, and IKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RFAI, PALI, ZNTL, and IKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFAI, PALI, ZNTL, and IKT Company Descriptions

Inhibikase Therapeutics NASDAQ:IKT

Palisade Bio NASDAQ:PALI

RF Acquisition Corp II NASDAQ:RFAI

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools